Rising Adoption of High-Throughput Genomic Platforms to Propel Market to $84.4 Billion by 2035

Genomics market was valued at $29.5 billion in 2025 and is projected to reach $84.4 billion by 2035, growing at a CAGR of 11.2% during the forecast period (2026-2035). Continuous innovation in next-generation sequencing technologies is significantly improving the efficiency and affordability of genomic analysis. Modern sequencing platforms are capable of processing large volumes of genetic data with greater speed and accuracy, enabling researchers to conduct extensive genomic studies at a lower operational cost. These advancements are particularly important for population-scale genomics programs and precision medicine initiatives that require the analysis of thousands of genetic samples. For instance, the UG 100 sequencing platform developed by Ultima Genomics, Inc. is designed to support high-throughput genomic workflows while targeting the concept of low-cost whole-genome sequencing. The platform utilizes advanced sequencing chemistry and high-capacity processing architecture to generate billions of DNA reads in a single run, thereby supporting large-scale genomic research.

Browse the full report description of “Genomics Market Size, Share & Trends Analysis Report by Deliverable (Products and Service), by Technology (Sequencing, PCR, Nucleic Acid Extraction & Purification, Microarray, CRISPR and Other), by Application (Drug Discovery & Development, Diagnostics, Agriculture & Animal Research, Precision Medicine and Other), and by End-User (Hospitals & Clinics, Academic & Research Institutions, Pharmaceutical & Biotechnology Companies, Clinical, Research Organizations (CROs) and Other), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/genomics-market

Advancements in high-throughput sequencing technologies are enabling large-scale biological studies by improving the speed and efficiency of genomic and proteomic analysis. Modern sequencing platforms are increasingly used in population-level research programs to generate extensive biological datasets that support disease research, biomarker discovery, and the development of precision medicine approaches. In January 2025, Ultima Genomics, Inc. announced that its UG 100 next-generation sequencing platform had been selected to support the UK Biobank Pharma Proteomics Project. The platform will be used alongside the Olink Explore HT system developed by Thermo Fisher Scientific Inc. to analyze more than 5,400 protein markers across approximately 600,000 biological samples. This large-scale research initiative is expected to generate one of the most extensive proteomics datasets to date, contributing to a deeper understanding of disease progression, biomarker identification, and the development of personalized treatment approaches.

Competitive Landscape and Strategic Developments in the Genomics Market

The global genomics market is characterized by the presence of several leading biotechnology and life science companies, including Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Thermo Fisher Scientific Inc., and QIAGEN N.V., among others. These companies play a critical role in advancing genomic technologies through continuous investments in research and development, product innovation, and strategic collaborations.

• In October 2025, 10x Genomics, Inc. announced the launch of the next generation of its Chromium Flex assay designed to expand scalability in single-cell research. The updated system introduces automation-compatible plate-based multiplexing, enabling researchers to analyze up to 384 samples and approximately 100 million cells per week using a 96-well plate format. The platform aims to support large-scale studies in areas such as functional genomics, translational research, and drug discovery by improving throughput and experimental efficiency.

• In October 2024, Myriad Genetics, Inc. announced a collaboration with Ultima Genomics, Inc. to evaluate the UG 100 sequencing platform for advancing clinical testing in oncology and reproductive genomics. The initiative includes integrating the platform into Myriad’s laboratory to assess its potential for improving performance and cost efficiency in applications such as molecular residual disease (MRD) testing and prenatal screening. The collaboration will explore the use of whole-genome sequencing and ppmSeq technology to support the development of next-generation clinical diagnostics.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-  
• Deliverable
• Technology
• Application
• End User
• Competitive Landscape – Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Thermo Fisher Scientific Inc., and QIAGEN N.V.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Genomics Market Report Segment

By Deliverable

• Products
• Services

By Technology

• Sequencing
• PCR
• Nucleic Acid Extraction & Purification
• Microarray
• CRISPR
• Other

By Application

• Drug Discovery & Development
• Diagnostics
• Agriculture & Animal Research
• Precision Medicine
• Other

By End User

• Hospitals & Clinics
• Academic & Research Institutions
• Pharmaceutical & Biotechnology Companies
• Clinical Research Organizations (CROs)
• Other

Global Genomics Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/genomics-market